Advertisement

Topics

Cerulean In Deal With Novartis To Develop NDCs; Gets $20 Mln Firm Commitment

09:15 EDT 19 Oct 2016 | FinanzNachrichten

BASEL (dpa-AFX) - Cerulean Pharma Inc. (CERU), a clinical-stage company developing nanoparticle-drug conjugates or NDCs, Wednesday said it has entered into a strategic collaboration with Novartis ...

Original Article: Cerulean In Deal With Novartis To Develop NDCs; Gets $20 Mln Firm Commitment

NEXT ARTICLE

More From BioPortfolio on "Cerulean In Deal With Novartis To Develop NDCs; Gets $20 Mln Firm Commitment"

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...